

Research Letter

High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data

Takanao Hashimoto, PhD^{1,*}, Akihiko Ozaki, MD, PhD², Divya Bhandari, MHS³, Toyooki Sawano, MD⁴, Ranjit Sah, MD⁵ and Tetsuya Tanimoto, MD⁶

¹Department of Pharmacy, Sendai City Medical Center, Sendai, Miyagi, Japan, ²Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima 972-8322, Japan, ³Medical Governance Research Institute, Tokyo 108-0074, Japan, ⁴Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima 972-8322, Japan, ⁵Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal and ⁶Internal Medicine, Navitas Clinic Kawasaki, Kanagawa 210-0007, Japan

*To whom correspondence should be addressed. Takanao Hashimoto, PhD, Department of Pharmacy, Sendai City Medical Center, 5-22-1, Tsurugaya, Miyagino-ku, Sendai, Miyagi 983-0824, Japan. Tel: +81-22-252-1111; Fax: +81-22-252-0454; Email: pharm.hashimoto@gmail.com

Submitted 12 April 2021; Revised 20 May 2021; Accepted 2 June 2021

Key words: BNT162b2 mRNA Covid-19 Vaccine, anaphylaxis, safety, Japan

To contain the coronavirus disease 2019 (COVID-19) pandemic, vaccine development and rollout have progressed rapidly around the world. After successful COVID-19 vaccine development, following the past examples of vaccine-preventable diseases,¹ nationwide vaccination programmes have been under way swiftly on a global scale. The BNT162b2 mRNA COVID-19 vaccine (Comirnaty, Pfizer-BioNTech, USA) is one of the vaccines granted earliest regulatory approval globally.^{2,3} In Japan, fast-track approval was granted to the vaccine on 14 February 2021, with the scheduled provision of ~140 million doses. The vaccine was the sole approved product as of May 2021, and the Japanese government set to prioritize vaccination in 4.84 million healthcare workers (HCWs) due to the sequential supply of limited doses.

The first round of Japan's vaccination programme against COVID-19 was initiated at 100 medical institutions eligible for priority vaccination for an estimated 40 000 HCWs from 17 February 2021.⁴ However, from early March 2021, the vaccination programme was extended to additional 4.8 million HCWs at other medical institutions before disclosing the initial safety data including anaphylaxis observed at preceding institutions. As of 16 March 2021, >350 000 HCWs had received the first dose of the vaccine, and >9000 HCWs had received the second dose. Belatedly, on 12 March 2021,

the Ministry of Health, Labour, and Welfare (MHLW) disclosed preliminary data of serious adverse reactions to the vaccine.

Therefore, using publicly available data by the MHLW, we conducted a secondary analysis of initial post-approval safety data concerning serious adverse reactions of anaphylaxis based on the vaccination programme in Japanese HCWs. For the diagnosis of anaphylaxis, each medical institution voluntarily reported possible cases based on their own judgement. Subsequently, the expert committee of the MHLW evaluated them based on the Brighton Collaboration case definition criteria (hereafter Brighton criteria).⁵ Statistical analysis was not performed due to the small number of subjects with anaphylaxis. Ethical considerations were not applied to this study.

The data included 181 184 HCWs who received one or more doses of vaccination by 11 March 2021.⁶ As shown in Table 1, 37 cases of anaphylaxis were observed, equating to 204.2 cases per million doses administered. Among them, only 17 (45.9%) cases were evaluated based on the Brighton criteria. Of which seven (41.1%) cases met the Brighton criteria 1, 2 or 3, resulting in 38.6 cases per million doses administered. The mean age of 37 cases was 40.4 years old, and a predominant cases were females (35, 94.5%). Twenty-one patients (56.8%) had a history of allergy as shown in Table 1. Within 30 min of vaccination, 31 (83.8%)

Table 1. The Characteristics of anaphylaxis cases

	All N = 37	Allergy histories	
		Yes (N = 21)	No (N = 16)
Mean age [range]	40.4 \pm 11.0 [23–58]	41.2 \pm 11.3	39.4 \pm 10.5
Female sex, N (%)	35 (86.5)	20 (95.2)	15 (93.8)
Time from vaccination to onset of anaphylaxis, min			
0–5	9	5	4
6–10	3	2	1
11–20	12	7	5
21–30	7	3	4
31–	6	4	2
Mean (N = 36) ^a	18.2 \pm 13.1	19.7 \pm 14.5	16.2 \pm 10.5
Brighton Collaboration case definition criteria			
1	2		2
2	4	1	3
3	1	1	
4, 5	10	7	3
Unevaluated	20	12	8
Overall drugs and vaccines		Details of allergies ^b	
Of these, influenza vaccine		15	
Analgesics or NSAIDs		5	
Antibacterial agents		4	
Hepatitis vaccine		2	
Contrast agents		2	
Overall foods		10	
Of these, egg		4	
Crustaceans (shrimps, crabs, etc.)		3	
Mackerel, buckwheat or wheat		Each 1	
Animal (Cat)		2	
Cosmetics		4	

Using data published by the Ministry of Health, Labour and Welfare as of 11 March 2021.⁵

All cases were the first dose of vaccination.

^aOne person who took 145 min to develop anaphylaxis (no history of allergy) was considered an outlier affecting the mean and was excluded from this analysis.

^bThe total does not necessarily add up to 21 because some patients have multiple allergy histories.

cases developed anaphylaxis. Those with allergic history had a longer onset time and a larger standard deviation than those without (19.7 \pm 14.5 vs 16.2 \pm 10.5 min). The outcomes were reported as recovery or mild improvement in all cases.

In Japan, the estimated cases per million doses administered were as high as 204.2 based on the spontaneous report, and they were 38.6 even when limited to the cases evaluated as level 1, 2 or 3 of the Brighton criteria. According to the US CDC, among a total of 9 943 247 doses of the BNT162b2 mRNA vaccine administered from 14 December 2020 to 18 January 2021, the anaphylaxis cases per million doses administered were 4.7.³ The underlying reasons of such high incidence of anaphylaxis in Japan are unknown, but the presence of polyethylene glycol (PEG) additive,⁷ which is also used in many cosmetic and pharmaceutical products is considered to be one of the reasons for inducing anaphylaxis by the BNT162b2 mRNA vaccine. Of the 37 HCWs who developed anaphylaxis, 57% had some history of allergy, and four patients had a history of cosmetics allergy, suggesting the potential involvement of PEG.

In Japan, based on ‘Immunization Act and the Pharmaceuticals and Medical Devices Act’, a spontaneous reporting system

for adverse reactions is already in place, but the information on the safety of the BNT162b2 mRNA vaccine after approval is still limited. We found that the MHLW had not fully evaluated vaccine anaphylaxis at the early phase of the vaccination programme, and it is understandable that the Japanese government tried to make up the delayed vaccine rollout compared with other high-income countries under the uncontrolled spread of COVID-19 in the country. However, precautions measures should be paid to vaccine hesitancy prevailing in Japan, as illustrated in the past human papillomavirus vaccine controversy.⁸ One of the first medical institutions that joined the vaccination programme is planning to conduct a safety survey (COV-Safe) using a social networking service for HCWs, and some hospitals have started their safety verification efforts.⁹ Also, the US CDC³ and the European Medicines Agency¹⁰ continue to monitor and publicize the safety of coronavirus vaccines on an ongoing basis. In order to promote the vaccination programme, further effort should be directed domestically and internationally to ensure the safety of vaccines with prompt evaluation and timely publication.

There are several limitations. First, the data about anaphylaxis were based on spontaneous reports without exact

definition from medical institutions, and some reported cases were not evaluated by the MHLW using the Brighton criteria. This might have led to over or underestimation of the effect. Second, although the high proportion of women experiencing adverse reactions is consistent with previous studies,³ a factor of gender bias is possible because all participants were HCWs. Third, we could not perform joint research with the MHLW using raw data, and our study included the publicly available data only, preventing us from conducting in-depth exploration of subject.

In conclusion, this study suggests that the incidence of anaphylaxis by the BNT162b2 mRNA vaccine may be higher in certain populations, such as the Japanese. Further safety studies that take into account ethnicity and race are necessary. Further global efforts should be directed to ensure the safety of vaccines with prompt evaluation and timely publication to promote effective vaccination programmes.

Authors' contributions

Takanao Hashimoto wrote the manuscript. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and approved the final manuscript.

Funding

None declared.

Conflicts of interest

Dr Ozaki reports personal fees from Medical Network Systems, MNES Inc. outside the submitted work. Dr Tanimoto reports personal fees from Medical Network Systems, MNES Inc., and Bionics co. Ltd, outside the submitted work.

References

1. Heymann DL, Wilder-Smith A. Successful smallpox eradication: what can we learn to control COVID-19? *J Travel Med* 2020; 27. doi: 10.1093/jtm/taaa090.
2. Polack FP, Thomas SJ, Kitchin N *et al.* Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020; 383:2603–15. doi: 10.1056/NEJMoa2034577.
3. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US–December 14, 2020–January 18, 2021. *JAMA* 2021; 325:1101–2. doi: 10.1001/jama.2021.1967.
4. [Japanese] Ministry of Health, Labour and Welfare: Vaccination for Healthcare Providers against the New Coronavirus. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_iryuujuuisha.html (20 Mar 2021, date last accessed).
5. Rugeberg JU, Gold MS, Bayas JM *et al.* Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine* 2007; 25:5675–84. doi: 10.1016/j.vaccine.2007.02.064.
6. [Japanese] Ministry of Health, Labour and Welfare: The 53rd Immunization and Vaccine Adverse Reactions Review Committee. https://www.mhlw.go.jp/stf/newpage_17208.html (20 March 2021, date last accessed).
7. Bruusgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. *Clin Exp Allergy* 2021; 51:463–70. doi: 10.1111/cea.13822.
8. Ozawa K, Hineno A, Kinoshita T *et al.* Suspected adverse effects after human papillomavirus vaccination: a temporal relationship between vaccine administration and the appearance of symptoms in Japan. *Drug Saf* 2017; 40:1219–29. doi: 10.1007/s40264-017-0574-6.
9. [Japanese] National Mie Hospital: Newsletter (March 2021). https://mie.hosp.go.jp/common/letter/nl_2103_02.pdf (21 March 2021, date last accessed).
10. European Medicines Agency: COVID-19: Latest Updates. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates> (24 March 2021, date last accessed).